were younger and had higher levels of hip-related pain and disability. The LBP group also had a higher number of painful spinal levels and pelvic pain provocation tests. Results should be interpreted with caution due to the low sample size. Further research is warranted to explore the cause and effect relationship and underlying pain mechanisms associated with co-existing hip OA and LBP.
groups achieved a reduction of !30% in the WOMAC pain subscale score from baseline and a majority of patients achieved a reduction of !50% at week 12 based on continuous responder analysis (Table) . No patients in the DSPCC 35 mg TID group and 2 patients (1.9%) in the DSPCC 35 mg BID group withdrew from the study due to lack of efficacy compared with 6 patients (5.8%) in the placebo group.
Conclusions: Treatment with DSPCC 35 mg TID and BID resulted in clinically meaningful improvements in pain in this study in patients with OA of the hip or knee. Purpose: Conservative treatments are especially in patients with GH-OA important, since shoulder arthroplasty has its limitations. In this systematic review we will evaluate the current evidence regarding the efficacy of intra-articular infiltration treatment options in patients with glenohumeral osteoarthritis (GH-OA). Methods: The following databases are searched: Pubmed/Medline, Cochrane Clinical Trial Register, Embase and the WHO clinical trial register. All intra-articular injection products used for the treatment of shoulder OA in humans are included. Results: A total of 8 studies could be included in this review. Hyaluronic acid (HA) showed effect sizes of 2.07, 2.02 and 2.11 at 6, 12 and 26 weeks follow-up, respectively. Placebo (1.60 , 1.82 and 1.68) also showed stable effect sizes at the same time points. The efficacy of corticosteroids (CS) decreased rapidly at follow-up (1.08, 0.43 and 0.19). Although statistical significant, the maximum difference in effect sizes between HA and placebo was only 0.43 with absolute values between 2.0 and 6.4 on a 100-point VAS for pain. Conclusion: Intra-articular treatment with HA has a good efficacy at follow-up compared to baseline. However, the difference in efficacy between HA and placebo never reaches the minimal clinically important difference at any of the follow-up points. We are not able to give clear recommendations for the use of intra-articular CS injections in patients with GH-OA. In future research we recommend to focus on sufficiently powered randomized trials to compare the efficacies of HA, CS, placebo and other intra-articular treatment options in patients with GH-OA. Purpose: A randomized single-blind phase IIa trial was conducted in 28 patients with knee OA to determine both safety and efficacy of TG-C. TG-C is a cell mediated gene therapy that contains non-transduced (hChonJ) and transduced (hChonJb#7) human allogeneic chondrocytes. hChonJb#7 cells were transduced with TGF-b1 gene using retroviral vector, while hChonJ cells were not modified. The hChonJb#7 cells were then irradiated with gamma-ray for preventing a replication of the cell and went to a cell death. Methods: MR images acquired at baseline (pre-treatment), as well as 6 and 12 months post-treatment, were evaluated by two experienced musculoskeletal radiologists in a blinded fashion using a modified WORMS (Whole Organ Magnetic Resonance Imaging Score) method. After this scoring, the images were presented to the two radiologists again, in time sequence, and radiological impressions were generated for cartilage, and any significant visible trends or changes were identified. During the un-blinded radiological evaluation a set of patients was noted to have improvements in the cartilage.
Results: The following improvements were observed: full thickness cartilage defect filling, generalized cartilage thickening in the defect area, and improvement or resolution of cartilage blisters. One patient showed several of these findings, and additionally showed considerable bone regeneration (bone remodeling) and cartilage regeneration in the trochlea, restoring the trochlea shape. Although these patients demonstrated many areas of improvement, in some patients there was evidence of progression of OA as well.
Conclusions: Based on these findings, there was an indication that in certain cases this treatment induced cartilage regeneration. Purpose: Inflammation and vascular disease are important in the pathogenesis of osteoarthritis. Low dose aspirin has anti-inflammatory and vasculoprotective effects. This study examined whether use of low dose aspirin affects change in knee cartilage volume in osteoarthritis. Methods: Participants from the Melbourne osteoarthritis cohort were classified as users and non users of aspirin based aspirin use (<300 mg/ day) at baseline. Participant's knees were imaged twice over 2 years. Medial and lateral tibial cartilage volumes were measured and change in cartilage volume was calculated.
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Results: Twenty one (18%) of participants were aspirin users at baseline. After adjustment for age, gender, body mass index and severity of radiographic change, annual change in medial tibial cartilage volume was À43 mm 3 (95% confidence intervals (CI) À94, 5) in aspirin users and À101 mm 3 (95% CI À124, À77) in non-users (P ¼ 0.048 for difference Phase II: Delphi survey A 3-round Delphi survey with patients and clinicians is being undertaken to achieve consensus in the reduction of the long-list of pain features to a core outcome set. In round 1, participants are asked to rate the importance of assessing each pain feature from 1-9 (very important to very unimportant). Those pain features given an importance rating of 7-9 by at least 70% of each of the two panels (patients and clinicians) and rated as 1-3 by less than 15%, or given an important rating of 7-9 by 90% or more members of one panel, are retained and carried forward to round 2. In round 2, participants are provided with group feedback and asked to re-rate the pain features. In round 3, participants are asked to rate their level of agreement that each pain feature should be included in a core outcome set. Results: Phase I: identification of pain features A long-list of 56 pain features was developed from the systematic review, focus groups and brief interviews with patients. The features identified focused on pain intensity, temporal aspects of pain, pain with activities/movements, pain interference, recovery and pain after TKR, emotional aspects of pain and use of pain medications. Phase II: Delphi survey 123 participants have been recruited into the Delphi survey (80 patients with chronic pain after TKR and 43 clinicians with relevant experience). In round 1, participants rated the importance of the 56 pain features identified in Phase I. Of these 56 pain features, 33 were retained and carried forward to round 2. Rounds 2 and 3 of the Delphi survey are currently ongoing and will be completed by January 2014. The core outcome set will be finalised by March 2014 and ready for presentation at the OARSI conference in April 2014.
